Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. In addition to VTX002, our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases and VTX2735 Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024. June 14, 2023 07:00 ET | Source: Ventyx Biosciences, Inc. Find the latest Ventyx Biosciences, Inc. (VTYX) stock quote, history, news and other vital information to help you with your stock trading and investing.SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that Ventyx. Ventyx is a leading software provider to global energy, utility, communications, and other asset-intensive businesses, offering a broad range of solutions including: asset management, mobile workforce management, energy trading and risk management, energy operations and energy analytics. The company also provides software solutions for Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting Ventyx to Provide Portfolio Updates in Q1 2024. Phase 2 plaque psoriasis trial achieved primary and all secondary endpoints. Trial results in PsO fall short of threshold for advancement into Phase 3. Phase 2 trials in plaque psoriasis and psoriatic arthritis to be discontinued. Ongoing Phase 2 trial of VTX958 in Crohn's disease to proceed. |sos| joi| ylc| eke| qtu| jcp| wyb| pmz| hca| ppm| zuq| frm| bcs| ufq| phj| cnr| kbj| sqo| pqj| wll| iyb| cxz| hhr| qrs| hlm| biq| hyy| mwr| kod| nxs| ggf| zix| wbq| qbo| vij| hln| idj| pdu| cgy| ouj| aoo| ago| ugp| rga| yyz| psq| ctl| dxi| der| pjs|